Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Cancer Lett. 2018 Nov 10;442:310–319. doi: 10.1016/j.canlet.2018.11.012

Fig. 1. SRC-3 overexpression correlates with the poor prognosis in PDAC patients.

Fig. 1.

(A) SRC-3 protein expression levels in tissues from PDAC patients were detected by immunohistochemistry (IHC) assays. SRC-3 protein is highly expressed in 9 of 11 tested PDAC tissues but not detectable in all PDAC paired adjacent normal pancreas tissues. SRC-3 IHC staining of tissues from 3 PDAC patients is presented here (scale bar: 50 μm). (B) SRC-3 protein levels, as measured by Western-blotting, are significantly high in most pancreatic cancer cell lines, and are comparable with lung cancer cell lines A549, H1975 and H1299, and breast cancer cell line MCF-7, but not detectable in normal pancreas duct cell line HPDE. (C) TCGA patients with a higher SRC-3 mRNA expression level have obviously shorter overall survival time than those with a lower SRC-3 level (P < 0.0148, log-rank test).